We use cookies to give you a personalized experience (to suit your online behavior on this, and other, sites) for our ads, content and communications; to improve the site; to operate the site; and to remember your preferences. Click "Learn more" for more details, or to adjust the settings. You can change your mind at any time by visiting "Cookie Preferences". Any personal data about you will be used as described in our Privacy Notice.
IQOS clinical studies
We continue informing you about what we know about IQOS. This time you will learn more about our extensive scientific assessment, including clinical studies, which show that switching completely to IQOS is likely to present less risk to your health.
The development of innovative tobacco heating devices has taken more than 20 years of research and development, and required an investment in this new technology and research which has already reached 4.5 billion US dollars.
The data & results from our scientific studies are the basis of all our messages.
We have 10 clinical studies, conducted in Europe, Japan and the USA, which now includes a study with 6 months of follow-up, looking at favorable changes in smoker who switch to IQOS compared to those who continue to smoke cigarettes. In addition, we supporting evidence on the potential for risk reduction from the 18 non-clinical studies that vary in size and duration – from a few days to up to 18 months.
Based on the totality of the scientific evidence to date, switching completely to IQOS is likely to present less harm to your health than continuing to smoke.
PMI publishes its research on tobacco harm reduction and our smoke-free products in peer-reviewed scientific journals. Our scientific research on IQOS is published using the scientific product description “Tobacco Heating System” or “THS”.
* Source: Average of the reductions in the concentrations of a broad range of harmful and potentially harmful chemicals measured in the IQOS aerosol compared to those measured in the smoke of more than 1,600 cigarette brands in over 40 countries between 2008 and 2017. Aerosol and smoke collections performed under the Health Canada Intense machine-smoking regime. Reduction calculations exclude nicotine.
The development of innovative tobacco heating devices has taken more than 20 years of research and development, and required an investment in this new technology and research which has already reached 4.5 billion US dollars.
The data & results from our scientific studies are the basis of all our messages.
We have 10 clinical studies, conducted in Europe, Japan and the USA, which now includes a study with 6 months of follow-up, looking at favorable changes in smoker who switch to IQOS compared to those who continue to smoke cigarettes. In addition, we supporting evidence on the potential for risk reduction from the 18 non-clinical studies that vary in size and duration – from a few days to up to 18 months.
Based on the totality of the scientific evidence to date, switching completely to IQOS is likely to present less harm to your health than continuing to smoke.
PMI publishes its research on tobacco harm reduction and our smoke-free products in peer-reviewed scientific journals. Our scientific research on IQOS is published using the scientific product description “Tobacco Heating System” or “THS”.
Important information: this does not mean IQOS is risk free.
* Source: Average of the reductions in the concentrations of a broad range of harmful and potentially harmful chemicals measured in the IQOS aerosol compared to those measured in the smoke of more than 1,600 cigarette brands in over 40 countries between 2008 and 2017. Aerosol and smoke collections performed under the Health Canada Intense machine-smoking regime. Reduction calculations exclude nicotine.